Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| It's growing today, albeit at a lesser pace, and the opportunities for it to grow into the future are very strong |
| We had another solid quarter with total revenue increasing 9%, with software up 10% and services up 5% |
| To start off, I am pleased with our team's successful acquisition of Immunetrics, a well-respected modeling and simulation company |
| As such, all users will be able to benefit from this major advancement in the new ADMET Predictor Version 11 release that is expected in the fourth quarter |
| The benefit of that is that the -- really the quality of the backlog is much stronger |
| We are very excited to welcome the Immunetrics team that brings proven QSP technology, a strong reputation in the market and incredible scientific talent to Simulations Plus |
| By joining forces, we believe we can establish a leading position in these rapidly growing therapeutic areas |
| Our team delivered solid results this quarter despite a challenging operating environment |
| The compelling value proposition that biosimulation delivers continues to grow, especially with new advancements in technology, and expanding impactful use cases |
| But I mean, we continue to have pretty good free cash flow that we're paying dividends out from |
| On a positive note, there has been good uptake of our price increases throughout the fiscal 2023, which we think demonstrate the value of our products and services |
| Our renewal harmonization strategy is providing significant benefits to smoothing out our contract renewal timing and seasonality impacts |
| We delivered 9% top-line growth year-over-year, driven primarily by strong revenue in our software segment, which was up 10%, while service revenue increased 5% over last year |
| From a profitability standpoint, we delivered strong gross margins of 82%, which reflected a favorable mix of higher margin software sales as well as the ability to pass on price increases |
| Overall, we're pleased with our performance |
| That said, our software revenue grew 10% in the quarter, benefiting from strong uptake of our price increases, good renewal rates and upsells and the addition of 17 new customers |
| Our top-line growth reaped some benefits from our renewal harmonization initiative, which we implemented at the beginning of this year, and is proceeding as planned |
| We have been executing on our strategic priorities and, as a result, are delivering profitable growth, generating cash and strong returns for our shareholders |
| Largely due to more favorable renewal harmonization, we saw robust software revenues for MonolixSuite, which grew 84% year-over-year |
| We have made some significant strides in the third quarter and I'm very proud of our teams collaborating with one another and with our clients to deliver exceptional work |
| As such, we remain well positioned to meet our stated goals for fiscal 2023, which include: year-over-year revenue growth in the range of 10% to 15%; total revenue between $59.3 million to $62.0 million; software revenue mix between 60% and 65%; services revenue mix 35% to 40%; diluted EPS of $0.63 to $0.67 |
| We believe that over time our Consult and Coach program will gain meaningful traction by training and expanding in-house client expertise with the goal -- the end goal of driving incremental software licensing revenues |
| This innovative program provides clients with access to our cutting-edge software and valuable learning opportunities |
| In conclusion, our ability to create value for our customers by using innovative solutions is transforming drug development R&D, optimizing treatment options and improving patient lives |
| The service business, as we start getting into the summer months, which can be disruptive, but coming to the quarter with good backlog to support expectations in the fourth quarter |
| On the international front, China was a strong performer with 29% revenue growth, mostly from GastroPlus and ADMET Predictor products |
| So from a price increase perspective, from upsell perspective, from a cross-selling scenario, new customers, pretty good statistics in terms of the GastroPlus performance, but the harmonization has pushed some revenue into the fourth quarter |
| GastroPlus, unlike the contrast here is Monolix that had a great quarter with 80%-plus growth in the third quarter, they benefited from the harmonization process by seeing more of their license of the renewals dislocate out of first and second quarter and a little bit forward from fourth quarter into third quarter, and so they saw that benefit, we saw that benefit with Monolix from harmonization in the third quarter |
| PKPD services revenues grew 2%, reflecting the shift to higher margin time and material contracts, which represented 42% of projects this quarter and contributed to expanding our services gross margin |
| And then, in terms of software growth, up, I think, around 12% -- I'm sorry, 10% year-over-year shows a very good uptick, especially relative to 1Q -- fiscal 1Q of '23 |
| Statement |
|---|
| Gross margin for the quarter declined slightly to 82%, reflecting softer margins in our services segment |
| For example, this quarter's GastroPlus revenues declined 2% year-over-year due to the timing and harmonization of the renewal contracts |
| We saw that began to slow at that point in time and hence our reduced guidance at the beginning of the year |
| As previously mentioned, large pharma spending constraints and small biotech funding challenges have impacted some renewals and upsell opportunities |
| Software gross margin was down slightly to 91% from 92% last year and services margins came in at 63%, primarily due to lower margin work on grants |
| Net income decreased 18% to $9.4 million and diluted earnings per share decreased to $0.46 |
| During the third quarter, small biotech, large pharmaceutical and CRO customers remained more cautious and we did see several non-renewals from smaller biotechs |
| Income from operations decreased 17% to $4.1 million in the quarter, while operating margin was 25% compared to 33% last year |
| Income from operations decreased 37% to $9 million, while operating margin was 20% compared to 34% last year |
| However, as I've mentioned in previous calls, our industry is not immune to macroeconomic pressures and the current environment is challenging |
| Renewal would be a challenging market |
| We anticipated these challenges this past October when we provided our fiscal '23 guidance of 10% to 15% revenue growth after delivering 16% revenue growth in fiscal year '22 |
| They've delivered in a more challenging environment to our expectations here this year |
| Net income decreased 2% to $4 million and diluted earnings per share remained at $0.20 |
| Large Pharma as well, I mean, we saw that in their budgetary cycle of October, November of last year that for different reasons, not their funding necessarily, but macroeconomic conditions causing them to be more cautious and prudent in terms of their budgets coming into fiscal -- their calendar year, fiscal year of '23 |
| It's little tough with a short quarter here, the close of the transaction into the quarter |
| Services backlog declined 6% to $16 million and our services team performed 212 projects during the quarter, 16 more than this time last year |
| And so the disruption to that segment of the market has been long term here now |
| And by account renewal fee in the mid-80%s, that one's come down from maybe more typically in the high 80% down to the mid-80%s |
| Total services projects worked on during the quarter increased 8% compared to last year and backlog decreased by approximately $1 million from last year to $16 million |
Please consider a small donation if you think this website provides you with relevant information